WYC209

SKU: orb1221041

Description

WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).

Key Properties

• CAS Number: 2131803-90-0
• MW: 368.45
• Purity: >98% (HPLC)
• Formula: C₂₀H₂₀N₂O₃S
• SMILES: CCOC(=O)c1cnc(nc1)C#Cc1ccc2c(c1)C(C)(C)CCS2=O
• Target: Retinoid Receptor
• Solubility: DMSO: 80 mg/mL (217.13 mM);Water: Insoluble

Bioactivity

• In Vivo:
  WYC-209 (0.022-0.22 mg/kg; i. v. ; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases. Animal model: Female immune-competent C57BL/6 mice. Dosage: 0.022, 0.22 mg/kg. Administration: Intravenous injection; once every two days for 25 days. Result: Four out of eight mice formed lung metastases at dose of 0.022 mg /kg, only one out of eight mice formed lung metastases at dose of 0.22 mg/kg.
  Read more...
• In Vitro:
  WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect. Apoptosis Analysis Cell line: A2780, A549, MCF-7, MDA-MB-435s, A375 cells. Concentration: 10 μM. Incubation time: 24 hours. Result: TRCs failed to resume growth 5 days after the drug washout.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Retinoid Receptor